Evidence map›Paper›PMID 38800757›Full record

ArticleFrontiers in microbiology2024

Evaluation of a real-time PCR assay performance to detect

Ida Parwati, Lidya Chaidir, Muhammad Yunus, Maya Marinda Montain, Dini Budhiarko, Siti Fatimah Selasih, Ryan Bayusantika Ristandi, Rifky Waluyajati Rachman, Raden Desy Nurhayati, Imran Pambudi and 1 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ida ParwatiDepartment of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Lidya ChaidirDepartment of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Muhammad YunusStem Cell and Cancer Institute, PT. Kalbe Farma, Jakarta, Indonesia.
Maya Marinda MontainUnit Pelayanan Fungsional Balai Besar Kesehatan Paru Masyarakat Bandung (UPF BBKPM), Bandung, Indonesia.
Dini BudhiarkoStem Cell and Cancer Institute, PT. Kalbe Farma, Jakarta, Indonesia.
Siti Fatimah SelasihStem Cell and Cancer Institute, PT. Kalbe Farma, Jakarta, Indonesia.
Ryan Bayusantika RistandiWest Java Provincial Health Laboratory, Bandung, Indonesia.
Rifky Waluyajati RachmanWest Java Provincial Health Laboratory, Bandung, Indonesia.
Raden Desy NurhayatiDr. H. A. Rotinsulu Lung Hospital, Bandung, Indonesia.
Imran PambudiDirectorate General of Diseases Prevention and Control, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia.
Akterono Dwi BudiyatiStem Cell and Cancer Institute, PT. Kalbe Farma, Jakarta, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis (TB) is one of the major global health issues due to its high mortality rate, especially in low- and middle-income countries. One of the key success points of the TB eradication program is early TB diagnosis, which requires rapid and accurate diagnostic testing. This study aimed to evaluate the performance of a newly developed RT-PCR kit (Indigen MTB/DR-TB RT-PCR) in a routine TB clinical setting. Method: A multi-fluorescence RT-PCR assay was designed and developed to detect regions within Result: The performance of Indigen MTB/DR-TB RT-PCR to detect MTB was assessed using 610 sputum specimens obtained from suspected patients. The overall sensitivity and specificity were 94.12% (95% CI: 90.86-96.48%) and 98.32% (95% CI: 96.20-99.46%), respectively. When the analysis was performed on AFB smear-negative TB subjects (386 subjects), a lower sensitivity level was found at 78.57% (95% CI: 68.26-86.78%), while the specificity level remained similar at 98.34% (95% CI: 96.18-99.46%). The overall performance of Indigen MTB/DR-TB RT-PCR to detect MTB showed substantial agreement with the MTB culture method (kappa value 0.93). In comparison to DST, the sensitivity and specificity levels of Indigen to detect RIF resistance or INH resistance were 78.2% (95% CI: 61.8-90.2%) and 82.8% (95% CI: 64.2-94.2%), respectively, while the specificity level for both groups was at 100% (95% CI, 87.7-100%). Conclusion: Indigen MTB/DR-TB RT-PCR demonstrated reliable performance for TB molecular diagnostic testing and can be implemented in routine TB diagnostic settings.

Indexed as

diagnosticIndigenINH resistanceMycobacterium tuberculosisreal-time PCRRIF resistance

Identifiers

PMID38800757
PMCPMC11123600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.